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INTRODUCTION
Recent progress in parasite immunobiology has led to the identification of several
plasmodial antigens representing the target of the protective antibody response of the
infected host. As a consequence, some of these antigens have been envisaged as potential
malaria vaccines in man. However, in spite of these achievements, the fine mechanisms
which lead to the development of a state of partial protective immunity or to the
triggering of immunopathology during malaria infection are not yet fully understood.
Thus, it may be appropriate to evaluate the relative importance of individual host
immune responsiveness to parasite epitopes involved in the induction of immunity, or
of some immunologically mediated adverse reactions such as glomerulonephritis,
anaemia, thrombocytopenia, and cerebral syndrome.
We have addressed this question using two differing approaches. First, the role of
the genetic background of the host in regulating the intensity of the immune response
against the repetitive epitope of Plasmodium falciparum circumsporozoite (CS) protein
was studied. Second, the involvement of immune mechanisms in some complications
of malaria, such as cerebral manifestations and thrombocytopenia, were investigated,
with particular attention to the role played by certain T cell subsets.
HOST IMMUNE RESPONSE TO PLASMODIUM EPITOPES: CAN GENETIC
RESTRICTION LIMIT THE EFFECTIVENESS OF FUTURE MALARIA VACCINES?
It was shown in experimental animal models and in human volunteers that inacti-
vated malaria parasites were able to confer immune protection against infectious
challenges (reviewed by Cochrane, Nussenzweig & Nardin, 1980). The production of
monoclonal antibodies directed against plasmodial antigens and the progress achieved
in molecular biology led to the characterization of several antigens able to confer some
degree of immune protection against malaria infection (reviewed by Drager-Dayal &
Lambert, 1986).
One of the most extensively studied malaria antigens is the circumsporozoite (CS)
protein. Individuals living in malaria-endemic areas produce antibodies against these
proteins after natural malaria infections and the anti-sporozoite antibody titres increase
as a function of age: children under 2 years of age are mostly negative whereas the great
majority of adults over 40 years are positive (Nardin et al. 1979; Tapchaisri et al. 1983;
Zavala, Tarn, Nussenzweig & Nussenzweig; 1985a; Del Giudice et al. 1986a, b).
The CS proteins consist of an amino acid sequence tandemly repeated several times
and flanked by unrepeated sequences (reviewed by Nussenzweig & Nussenzweig, 1985).
Most monoclonal antibodies so far produced against sporozoites and most anti-
sporozoite antibodies induced after natural malaria infections bind specifically to the
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repeated amino acid sequence (Zavala, Cochrane, Nardin, Nussenzweig & Nussenzweig,
1983).
The repetitive epitope of P. falciparum CS protein consists of 4 amino acids
(Asn-Ala-Asn-Pro = NANP) repeated 37 times (Dame et al. 1984; Enea et al. 1984).
(NANP)n sequences have been now produced by both chemical synthesis (Zavala et al.
19856; Ballou et al. 1985) and by recombinant DNA technology (Young et al. 1985).
It has been shown that 3 (NANP) repeats represent the minimal size of the molecule
able to be recognized efficiently by specific antibodies (Zavala et al. 19856) and to prime
specifically murine T cells in vivo (Togna et al. 1986). (NANP)n peptides have been
successfully employed for the detection of anti-P. falciparum sporozoite antibodies by
means of enzyme-linked immunosorbent assay (Del Giudice et al. 1986a; Hoffman et al.
1986) or radio-immunometric assay (Zavala, Tam & Masuda, 1986). A large (NANP)40
synthetic peptide was used as coating antigen for ELISA in a longitudinal study
carried out in a rural community in Tanzania (Del Giudice et al. 19866). It was found
that, at 10 years of age, about half of the children who have been heavily exposed to
malaria infections did not develop anti-NANP antibodies. Furthermore, considerable
differences in antibody levels against NANP were observed in children living in different
households but exposed to the same epidemiological conditions, although their antibody
titres to asexual blood-stage antigens were similar. These data suggested that the genetic
background may be of particular importance for the regulation of anti-sporozoite
responses. (NANP)n synthetic peptides conjugated to carrier proteins and large
recombinant peptide carrying an amino acid sequence oiE. coli. were shown to be highly
immunogenic in mice and rabbits: the antibodies raised against them recognized
specifically P. falciparum sporozoites and inhibited the penetration of sporozoites into
cultured hepatoma and hepatic cells and their maturation into exo-erythrocytic forms
(Mazier et al. 1986).
The immunogenicity of (NANP)n sequences could be directly studied in our labora-
tories, both at T and B cell levels, using a novel large synthetic peptide consisting of
40 (NANP) repeats, (NANP)40, without any carrier. C57BL/6 mice (H-2b) responded
strongly to (NANP)40, producing high titres of IgG and IgM antibodies which also
recognized specifically extracts of Anopheles stephensi mosquitoes infected with
P. falciparum sporozoites. Congenic mice bearing the immunoglobulin allotype Ige
responded in the same manner, as well as the (C57BL/6 x BALB/c)Fl hybrid mice.
However, neither athymic C57BL/6 nu/nu nor congenic C57BL/6.H-2k mice produced
anti-(NANP)40 antibodies (Del Giudice et al. 1986c). These results suggested that the
production of antibodies to carrier-free (NANP)n peptides (i) T cell dependent, (ii)
not dependent on the immunoglobulin allotype of mice and (iii) possibly linked to
particular haplotypes of the murine major histocompatibility complex (MHC) H-2.
In addition, 14 mouse strains bearing 9 different H-2 haplotypes were immunized with
(NANP)40 without carrier but, surprisingly, only H-2b mice (C57BL/6, C57BL/10 and
BXSB) were able to mount a strong antibody response against the peptide, all non-H-2b
mouse strains tested being completely unresponsive (Fig. 1). The anti-(NANP) antibody
response was shown to be strictly linked to the presence of the b allele in the I-A region of
the H-2 gene complex (Del Giudice et al. 1986c). In fact, only I-Ab recombinant
B10.A(5R) mice produced such antibodies. Furthermore, the antibody response against
(NANP)40 was extremely weak in B6CH-2bm12 mutant mice, which carry a gene
conversion leading to the substitution of 3 amino acids of the beta 1 domain of the I-Ab
beta chain (Mclntyre & Seidman, 1984). These findings were confirmed by experiments
employing (NANP)-specific T cell clones derived from lymph node cells of C57BL/6
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Fig. 1. IgG antibody response against (XAXP)40 in 14 mouse strains bearing 9 different H-2
haplotypes. Mice were immunized at the base of the tail with 50 fi\ of (XAXP)40 (20 /ig) in
Complete Freund's Adjuvant. Four weeks later the mice were boosted in the same way with
the peptide in Incomplete Freund's Adjuvant. Sera were taken 7 days later and tested
individually by ELLSA, employing (XAXP)40 at a concentration of 1 fig/m\ for coating the
plates. Solid bars represent the geometrical mean of the titres obtained in each group. Titres
of less than 1:200 were considered to be negative.
mice immunized with carrier-free (NANP)40 (Togna et al. 1986). These L3T4+ T cell
clones proliferated only in the presence of irradiated spleen cells from C57BL/6 or
B10.A(5R) mice as antigen presenting cells (APCs), not in the presence of APCs from
B10.A(4R) nor from B6CH-2bm12 mice. T cell clone proliferation was specifically
inhibited by adding an anti-I-Aft monoclonal antibody to the cultures. A similar genetic
restriction of the immune response to NANP, at the T cell level, was recently reported
by Good et al. (1986). The inability to respond to (NANP)40 could be overcome in
non-H-2b mice when they were immunized with the peptide conjugated to a carrier
protein (Del Giudiee et al. 1986c).
Thus, the murine antibody response to (NANP)n is genetically restricted and strictly
linked to the presence of a particular allele (b) in the 1—A region of the H-2 complex.
This exceptional restriction is surprising since, usually, mice of more than one H-2
haplotype are able to respond to a given epitope (reviewed by Schwartz, 1986). One can
postulate that an analogous genetic control of the antibody response to (NANP)B
peptides could also exist in man, and may limit the effectiveness of a vaccination with
the (NANP)re peptides. On the other hand, such genetic control could also exist for the
antibody response to whole P. falciparum sporozoites. This could also explain the
observation that a significant percentage of young subjects living in malaria endemic
areas do not develop anti-NAXP antibodies (Zavala et al. 1985a; Del Giudiee et al.
5-2
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1986a, b). Further studies are required in order to determine the actual role played by
MHC gene products in man in controlling the ability of different individuals to respond
to sporozoites and/or to sporozoite peptides.
It was shown that the H-2 restriction existing towards the immunodominant
repetitive epitope of P. falciparum CS protein is overcome when a peptide—carrier
protein conjugate is employed as an immunogen. In these conditions, there is an
expansion of B cells specific for the repetitive epitope, but often no priming of
NANP-specific T cells. Thus, individuals vaccinated with such conjugates may lack
sporozoite-specific T cells and, in endemic countries, would not benefit entirely from the
boosting effect provided by natural sporozoite inoculations.
CAN MALARIA VACCINES ENHANCE IMMU NO PATHOLOGY ? EVIDENCE FOR
IMMUNOLOGICAL MECHANISMS IN SOME COMPLICATIONS OF
EXPERIMENTAL MALARIA
In view of the presently available immuno-epidemiological data, it is conceivable that
any future malaria vaccines would only confer partial immunity against plasmodium
infection and one should expect a lack of vaccine efficiency in at least a small proportion
of immunized children. Therefore, it may be essential to evaluate the relative risk of
enhancing immunopathology by inducing an immune response towards selected
plasmodial epitopes before natural exposure to malaria infection. This concern is largely
based on experimental evidence suggesting that some major complications of malaria
could partly result from the immune response against parasite antigens. This is
particularly the case for glomerulonephritis, anaemia, thrombocytopenia, cerebral
malaria and tropical splenomegaly syndrome.
The pattern of individual immune responses, particularly at the T cell level, and the
relative involvement of certain identified plasmodium antigens have been studied in our
laboratory in relation to the development of some of these pathological reactions during
murine malaria.
Cerebral malaria
Cerebral symptoms accompanying acute falciparum malaria in young children and
in non-immune adults represent severe complications with a frequent fatal outcome.
The most common autopsy findings are vascular congestion and plugging of blood
vessels with heavily parasitized erythrocytes, petechial haemorrhages and reactive
gliosis (Polder, Jerusalem & Eling, 1983). The neurons usually show no obvious lesions
besides signs of anoxia associated with localized cerebral oedema in the perivascular
areas. Brain oedema is a common finding at autopsy (Aikawa, Suzuki & Gutierrez,
1980). However, recent studies have shown by computed tomography that cerebral
oedema may occur but is not a consistent feature of severe cerebral malaria (Looare-
suwan et al. 1983). In vivo damage to the endothelial cell, with resulting alteration of
capillary permeability has been reported in patients with cerebral malaria (Areekul.
Kasemsuth & Kanakakorn, 1984) and increased permeability of the choroid plexus has
been shown in rodent malaria (Depierreux, Hochmann, Herrera & Lambert, 1986). The
pathogenesis of these charges remains unknown, although various hypotheses have been
proposed: endothelial lesions (Knisely, 1961; Wash, 1979), with attachment of
monocytes to the endothelium (Rest & Wright, 1979; Rest, 1982); sequestration of
parasitized red blood cells in capillaries (Yoeli & Hargreaves, 1974; McPherson et al.
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1985); allergic reaction of the central nervous system to antigenic challenge (Toro &
Roman, 1978); T-cell-mediated cellular immune reaction (Wright, Masembe & Bazira,
1971; Finley, Mackey & Lambert, 1982) or T-cell-dependent humoral reaction involving
circulating immune complexes (Contreras, June, Perrin & Lambert, 1980; Rest &
Wright, 1979; Adam et al. 1981) and the activation of the complement cascade.
In man, indirect evidence of a T cell involvement in neurological complications is
provided by the observation of lower frequency of cerebral malaria in malnourished
children (Edington, 1967). Thymic atrophy (Watts, 1969; McFarlane, 1971) and func-
tional impairment of cell-mediated responses (McMurray, 1984) have been documented.
Immune mechanisms, and particularly T cell mediated immunity have been implicated
in the development of experimental cerebral malaria, since neurological complications
are less severe in neonatally thymectomized hamsters (Wright et al. 1971) and absent
in athymic nude BALB/c mice (Finley et al. 1982).
In our laboratory, a mouse model of cerebral malaria, after infection with Plasmodium
berghei asexual blood stages, was analysed. In this experimental model, a cumulative
mortality of about 90% between day 7 and day 15 of infection was observed in CBA
mice, which appeared to be genetically susceptible to the development of neurological
lesions. A particularly important feature of this model is that cerebral signs occurred
when anaemia was moderate and the parasitaemia relatively low. In addition, several
clinical and histopathological parameters were found to be similar to those observed
in patients with cerebral malaria (Jerusalem et al. 1983; Grau et al. 1986). Three lines
of evidence indicate that helper T lymphocytes play a significant role in the development
of murine cerebral malaria (Grau et al. 1986).
First, it was demonstrated that the in vivo depletion in L3T4+ helper/inducer T cells
induced by treatment of P. berghei-infected mice with an IgG2b monoclonal antibody
(MAb) directed against the L3T4 molecule, completely abrogated the occurrence of
cerebral malaria, although there was no modification of the infection itself (Grau et al.
1986). No protective effect was seen after treatment of infected mice with a MAb of the
same isotype directed against Ly.2+ T cell subset. The effectiveness of this treatment
by anti-L3T4 MAb in infected mice was demonstrated both phenotypically (depletion
of the corresponding T cell subset) and functionally (inhibition of the IgG antibody
response to a T-dependent antigen, tetanus toxoid).
Second, experiments were conducted in adult-thymectomized, irradiated and bone
marrow-reconstituted (AT x BM) CBA mice which appeared to be completely resistant
to the development of neurological lesions upon infection with P. berghei. These results
confirmed and extended the results obtained using athymic nu/nu mice (Finley et al.
1982) which suggested a role for T cells in the development of cerebral malaria. T cells
carrying the L3T4 phenotype were shown to be particularly involved in this syndrome
since reconstitution of AT x BM CBA mice with normal L3T4+ T cells rendered these
mice fully susceptible to the development of neurological complications. In contrast,
AT x BM mice reconstituted with the Ly.2+ T cell subset did not die acutely with
neurological signs but later developed severe anaemia and overwhelming parasitaemia
(Grau et al. 1986).
Third, there was an exacerbation of neurological signs and earlier mortality observed
after transfer of L3T4+ Ly.2" T cells from mice with cerebral malaria into infected
euthymic mice. This observation supported the hypothesis of an involvement of these
cells in the pathogenesis of cerebral malaria.
Humoral parameters of the immune reponse were also analysed in P. berghei-iniected
CBA mice (Grau et al. 1986). As previously suggested (Rosenberg, 1978; Finley et al.
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Fig. 2. Detection, by indirect immunofluorescence, of specific antibodies directed against
segmented sehizonts in the serum of a Plasmodium berghei-intected CBA mouse developing
cerebral malaria 9 days after infection.
Table 1. Effects of T-cell depletion or reconstitution on aw<i-Plasmodium antibody
response during infection.
AnW-Plasmodium antibodies
Specificity
Mice
Euthymic
Euthymic
+ anti-L3T4 MAb
-l-anti-Ly.2 MAb
AT x BM
ATxBM.4+
AT x BM.2+
IFA titre*
8173
469
729
420
3040
420
RF, TZ Seg. SZ
* Day 14.
1982) malaria-associated polyclonal B cell activation was found to be T cell dependent.
Indeed, in infected mice treated with anti-L3T4 MAb, there was a marked inhibition
of the increase in serum levels of IgG, IgM and circulating immune complexes (CIC)
compared with untreated infected animals. The specific anti-plasmodium immune
response was also studied, with particular attention to antibodies recognizing certain
stages of parasite development (Fig. 2, Table 1). In fact, in malaria-infected mice treated
with anti-L3T4 MAb, there was a significant decrease of the specific anti-plasmodium
antibody response but this response was in no way completely suppressed. The quality
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of the response appeared to be more specifically influenced by the treatment with
anti-L3T4 MAb. Antibodies directed against mature stages of plasmodium (polyseg-
mented schizonts) were consistently absent in the sera from those L3T4+ T cell-depleted
mice which were protected against cerebral malaria (Table 1). Moreover, anti-segmented
schizont antibodies were found in only 1 of 15 sera from day 8-infected euthymic CBA
mice without cerebral malaria. The absence of anti-segmented-schizont immune
response in the anti-L3T4 treated mice might be of importance in the protecting effect
of this treatment.
In addition, the hypergammaglobulinaemia and the increase in CIC levels, which were
absent in AT x BM mice, were restored in AT x BM mice reconstituted with normal
L3T4+ T cells (ATxBM.4+). Specific antibody levels indicated that AT x BM mice
responded quite poorly to malaria antigens. Although this response was only moderately
enhanced by the adoptive transfer of L3T4+ T cells, it is noteworthy that this transfer
led to the appearance of anti-segmented schizont antibodies, already detectable by day
10.
The data presented here indicate that experimental cerebral malaria is probably
mediated by immune mechanisms. Indeed, it was shown that the development of murine
cerebral malaria is not directly related to the degree of anaemia and parasitaemia, but
rather appears as the expression of immunopathological reactions of the infected host.
The importance of the functional integrity of lymphoid cells expressing the L3T4
phenotype (helper T cells) in the triggering of neurological complications was outlined
in these studies. One should note that L3T4+ T cells of different specificities for malaria
antigens may have different effects on the infection and, particularly, on the cerebral
complications.
Various functional relationships between L3T4+ T cells and neurological lesions
can be envisaged (Fig. 3). Firstly, the helper effect of L3T4+ T cells for the specific
anti-plasmodium antibody response may be of particular importance, since it was shown
that antibodies of certain specificities (segmented schizont antigens) are consistently
associated with the occurrence of cerebral malaria. This helper effect may also be exerted
in a less specific manner: malaria-associated polyclonal B-cell activation appears indeed
to be largely T cell dependent. Secondly, the activation of T cells in the presence of
properly presented malarial antigens results in the release of various lymphokines such
as interleukin 2, interleukin 3, colony-stimulating factor and y-interferon. The
production of y-interferon was demonstrated in vitro by T cells in the presence of
macrophages and parasitized erythrocytes (Ockenhouse, Schulman & Shear, 1984). This
was associated with the release of reactive oxygen species, participation of which has
been documented in acute vascular changes (Chan, Schmidley, Fishman & Longar,
1984) and suggested in the pathogenesis of cerebral malaria (Clark & Hunt, 1983; Clark,
Hunt & Cowden, 1987). Tumor-necrosis factor (TNF) is another intermediate produced
upon macrophage activation which is known to alter selectively endothelial cell
functions (Nawroth et al. 1986). Thirdly, L3T4+ T cells can also mediate delayed-type
hypersensitivity (DTH). However, the existence of local DTH-like reactions in the
cerebral compartment was not suggested by histological studies since there was no
accumulation of lymphocytes at the site of brain lesions (Jerusalem et al. 1983;
McPherson et al. 1985; Depierreux et al. 1986).
The relevance of these data to human pathology should be discussed. Indeed, it has
been suggested that immune mechanisms are not involved in the pathogenesis of human
cerebral malaria (see Warrell, this issue) because there was no evidence, at autopsy, of
cellular infiltrates nor of visible endothelial damage in the brain (McPherson et al. 1985).
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Fig. 3. Schematic representation of various mechanisms by which L3T4+ T cells can lead
to the triggering of cerebral vascular changes (see text for discussion). APC, antigen
presenting cell; CSF, colony-stimulating factor; seg. SZ, segmented schizonts; CIC, circulat-
ing immune complexes; TCP, thrombocytopenia; pRBC, parasitized red blood cells; PA.
plasminogen activator; TNF, tumour necrosis factor.
In our experiments in mice, there were no lymphoid cell infiltrates in the brain and the
vascular lesions were acute and localized to certain cerebral territories. Obviously, the
sole classical morphological analysis does not allow us to draw conclusions regarding
the existence of immunopathological mechanisms. However, since all these lesions were
prevented in mice with an impaired immune response and appeared again after
restoration of the L3T4+ T cell compartment, indirect mechanisms dependent on the
specific or non-specific immune response to malaria are probably involved in the
pathogenesis of the syndrome in mice. One cannot exclude the possibility that similar
indirect mechanisms are also responsible for the cerebral syndrome in man.
EFFECTS OF CYCLOSPORIN A ON CEREBRAL MALARIA
Cyclosporin A (CsA) is an immunosuppressive agent capable of interfering at several
levels with the immune response (Borel, Feurer, Magnee & Staehelin, 1977; Larsson,
1980; Bunjes, Hardt, Rollinghof & Wagner, 1981; Shevach, 1985). The T cell specificity
for the immunosuppressive effects of CsA was suggested by the failure of CsA to suppress
antibody response to bacterial lipopolysaccharide antigens in vivo in nude mice. Recent
data suggest that the major site of action of CsA is the inhibition of mRNA transcription
for the lymphokines interleukin 2 (IL-2), interleukin 3 (IL-3) and interferon-y (IFN-y)
(Kronke et al. 1984; Elliott et al. 1984; Granelli-Piperno, Inaba & Steinman, 1984:
Wiskocil et al. 1985). CsA inhibits lymphokine production in both helper and cytolytic
cells, but does not directly inhibit or block proliferative responses of cytolytic cells in
which proliferation can occur via an IL-2 independent pathway (Herold et al. 1986).
Because of the powerful inhibitory effects of CsA on helper T cells and since these helper
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T cells have been shown to play a major role in the pathogenesis of murine cerebral
malaria, the potentially beneficial effects of CsA were evaluated in the murine model
of P. berghei infection.
A direct toxic effect of CsA on malaria parasite has been documented (Thommen-
Scott, 1981; Nickell, Scheibel & Cole, 1982). CsA has therefore been administered at
different doses, especially at doses unable to exert any anti-parasite effect. It was shown
that, in these conditions, CsA as well as some CsA analogues were able to protect fully
more than 90% of treated animals (Grau et al. manuscript submitted). As little as 1 mg
CsA/kg body weight, given during 5 consecutive days once the infection had entered
its patent phase, displayed a strong protective effect on cerebral complications without
interfering at all with the progression of parasitaemia and without any detectable effect
on humoral immune responses. Higher doses of CsA delayed the increase of parasitaemia
and, as a consequence, cerebral malaria was delayed but in no way prevented as in mice
treated with lower doses. The mechanisms by which low doses of CsA exert their
protective effects on cerebral complications are not yet understood, but the in vivo
evaluation of post-translational inhibition of mRNA for various lymphokines is under
current investigation.
These results provide promising implications for treatment of malaria-infected
patients, with or without severe complications. Preliminary results have indicated
(J. F. Borel, personal communication) a beneficial effect of CsA in human patients with
cerebral malaria. This observation tends to support the hypothesis of an immuno-
pathogenesis of cerebral malaria.
MALARIA-ASSOCIATED THROMBOCYTOPENIA
Thrombocytopenia is a frequent complication in patients with severe malarial
infection (Beale, Cormack & Oldrey, 1972; Butler et al. 1973; Horstmann, Dietrich,
Bienzle & Rasche, 1981; Wilson, Neame & Kelton, 1982).
The mechanism of this thrombocytopenia remains poorly understood. The rapidity
of onset and recovery as well as reduced platelet survival (Skudowitz et al. 1973;
Horstmann et al. 1981) suggests that it is caused by increased platelet destruction.
Disseminated intravascular coagulation (DIC) has been considered as a possible cause
in some investigations (Dennis, Eichelberger, Inman & Conrad, 1967; Borochowitz,
Crosley & Metz, 1970) but, in recent years, it has been recognized that thrombocytopenia
is a very common and early sign of malaria infection, whereas DIC is distinctly
uncommon (Beale et al. 1972; Srichaikul et al. 1975; Vreken & Cremer-Goote, 1978).
Direct interactions between plasmodium and platelets have also been suggested.
Parasites have been demonstrated inside blood platelets by electron microscopy in both
human and experimental infections (Fajardo, 1973; Fajardo & Tallent, 1974; Fajardo,
1979), but the precise implications of this finding remain obscure. Immune mechanisms
may also mediate thrombocytopenia and can be potentiated by the generalized
reticulo-endothelial system (RES) hyperplasia found at autopsy and the increased RES
functional activity during acute malaria (Sheagren, Tobie, Fox & Wolfe, 1970). Immune
complexes which are present in the circulation of malaria-infected patients could play
a role in the peripheral destruction of platelets as well as red blood cells (Contreras
et al. 1980). Some evidence for such immune mechanisms has been provided by the
quantification of platelet-associated IgG (PAIgG) in patients with acute malaria
infection. Increased PAIgG levels are thought to be responsible for the rapid clearance
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of circulating platelets by the RES and are currently considered to be a criterion for
definition of immune thrombocytopenia (Kelton & Gibbons, 1982). Kelton, Keystone,
Proctor & Neame (1980) reported increased levels of PAIgG in the majority of patients
with malaria and thrombocytopenia. PAIgG returned to normal as the parasites were
cleared from the circulation and the platelet counts returned to normal values. Recently,
Kelton et al. (1983) demonstrated that, in patients with P. falciparum malaria and
thrombocytopenia, IgG binds to platelet-associated malarial antigens through its Fab
terminus, probably representing anti-platelet antibodies.
In our mouse model of infection with P. berghei asexual blood stages, thrombocyto-
penia develops as early as day 4 and its severity increases gradually until death.
Thrombocytopenia associated with P. berghei infection is likely to be due to an in-
creased peripheral destruction rather than a central hypoproduction of platelets, since in
infected mice, bone-marrow megakaryocytes were found in increased numbers and the
survival time of 111Indium-labelled platelets was reduced (Grau et al. manuscript
submitted). The role of immune mechanisms was confirmed by the observation of
increased amounts of IgG on platelets from infected animals. Elevated PAIgG correlated
inversely with platelet counts. In addition, it was shown that serum from infected mice
contains anti-platelet antibodies, as measured by an enzyme-linked immunosorbent
assay (ELISA) using platelet monolayers as the solid phase (Grau et al. manuscript
submitted). This assay was shown to be independent of the binding of circulating
immune complexes through the Fc receptor. The functional in vivo importance of these
serum anti-platelet antibodies was outlined by the fact that passive transfer of ultra-
centrifuged serum from P. berghei -infected, thrombocytopenic mice led to an immediate
drop in platelet counts in syngeneic recipients (Grau et al. manuscript submitted).
The occurrence and the degree of P. berghei-induced thrombocytopenia was found to
be dependent upon the T cell status of the host. Indeed, treatment of infected mice with
an IgG2b MAb directed against the L3T4 surface antigen protected these mice against
thrombocytopenia. In contrast, treatment with anti-Ly.2 MAb of the same isotype had
no protective effect on thrombocytopenia. Similarly, there was no significant thrombo-
cytopenia in AT x BM mice infected with P. berghei. The T cell dependency of
P. berghei-induced thrombocytopenia was further demonstrated in experiments using
AT x BM mice selectively reconstituted with normal L3T4+ or Ly.2+ T cell subpopu-
lations. Indeed, the susceptibility to develop thrombocytopenia upon infection with
P. berghei was restored only in AT x BM mice previously reconstituted with L3T4+
T cells. More direct evidence of the role of L3T4 T cells in the development of P. berghei-
induced thrombocytopenia was provided by another transfer. L3T4+ Ly.2^ T cells were
isolated from P. berghei-infected mice undergoing cerebral malaria and severe thrombo-
cytopenia. After elimination of contaminating parasitized erythrocytes, these cells were
adoptively transferred to normal syngeneic recipients and were able to elicit a significant
degree of thrombocytopenia.
Apart from antibody-mediated mechanisms, interactions between lymphoid cells and
platelets have been described in vitro (Coeugniet, 1979; Gengozian & Rice, 1982) and
might also play a role in the effect observed in such cell transfer experiments. Taken
together, these results indicate that, in this experimental model, the thrombocytopenia
which occurs during malaria infection displays all the parameters of an immunopatho-
logical complication. It is noteworthy that, in T cell-depleted mice, such as anti-L3T4,
monoclonal antibody-treated or AT x BM mice, the protection against thrombocyto-
penia paralleled the protection against cerebral malaria. Thrombocytopenia may thus
conceivably represent one of the multiple factors possibly involved in the triggering of
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182000085851
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 15:15:35, subject to the Cambridge Core terms of use, available at
Host immune, responsiveness in malaria SI33
cerebral complications of malaria, bv favouring the occurrence of brain haemorrhages
(Fig. 3).
CONCLUSION AND SUMMARY
Until recently, the immune response to plasmodia has been considered without
discriminating the relative importance of individual antigens or distinct epitopes in the
induction of this response. It now appears that the general rules which regulate the
operation of the immune system also apply to the immune responsiveness to single
plasmodium epitopes. Thus the development of anti-parasite immunity, as well as the
triggering of immunopathological manifestations, are probably strictly related to the
variety of individual patterns of immune responsiveness encountered in populations
exposed to the infection. These considerations are particularly relevant to the selection
of antigens as potential candidates for malaria vaccination in order to achieve protecting
efficiency without increasing the frequency of the well-known complications of acute
malaria.
The immune response to P. falciparum CS protein repetitive epitope, NANP, is likely
to be hampered by the requirement for an appropriate genetic background at the level
of the MHC genes. This phenomenon was clearly shown in mice since only I-Ab mice
were able to develop a proper T cell response and to produce anti-NANP antibodies after
immunization with carrier-free peptide.
Preliminary epidemiological studies in man indicate that the repeated natural
exposure to this epitope can induce an anti-NANP response but not in all individuals.
Therefore, the relative importance of the genetic regulation of the immune response to
denned plasmodium epitopes in man will have to be taken into account in order to avoid
inefficient vaccination in a significant proportion of individuals at risk.
The analysis of experimental models of malaria in rodents underlines the potential
risk of enhancing malaria-associated pathology by an inappropriate or a relatively
inefficient immunization against selected plasmodium antigens. Indeed, T cells of the
L3T4+ subset seem to play a central role in the pathogenesis of murine cerebral malaria
as well as in malaria-associated thrombocytopenia. The immune response to certain
asexual blood-form antigens may be critical for the pathological expression of the
disease. Obviously, potentially pathogenic responses are also genetically controlled and
possible vaccine side-effects may be restricted to a limited segment of the population.
However, in view of the large numbers of individuals exposed to malaria and likely to
be vaccinated, the risk of enhancing immunopathology should not be neglected.
This work was supported by UNDP/World Bank/WHO Special Programme for Research and
Training in Tropical Diseases and by the Swiss National Foundation, grant No. 3.826.0.83.
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